Literature DB >> 3304704

Review of lipid-lowering clinical trials in relation to observational epidemiologic studies.

H A Tyroler.   

Abstract

A review of the experimental clinical trials and observational cohort evidence relating serum cholesterol level and its reduction to risks of coronary heart disease (CHD) discloses strong similarities among the quantitative and qualitative relationships found in these studies. Not only are the risk functions similar, but the percent reduction observed is the same as that predicted from the population experience and is proportional to the degree of cholesterol lowering. Furthermore, the risk function is continuous from the highest to the lowest serum cholesterol levels studied. These findings confirm the lipid hypothesis and indicate that lowering serum cholesterol reduces CHD risk. The understanding and control of CHD requires a dual approach: (1) identification and treatment of high-risk individuals, and (2) modification of environmental and behavioral determinants to achieve more favorable distributions of serum cholesterol in populations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3304704     DOI: 10.1161/01.cir.76.3.515

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Beta-blockers, lipoproteins and non-insulin dependent diabetes.

Authors:  M D Feher; S G Rains; W Richmond; D Torrens; G Wilson; J Wadsworth; P S Sever; R S Elkeles
Journal:  Postgrad Med J       Date:  1988-12       Impact factor: 2.401

2.  A mathematical model for the determination of the optimum value of the treatment threshold for a continuous risk factor.

Authors:  M Cucherat; J P Boissel
Journal:  Eur J Epidemiol       Date:  1998-01       Impact factor: 8.082

3.  Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo.

Authors:  M J Rudling; E Reihnér; K Einarsson; S Ewerth; B Angelin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 4.  Lowering cholesterol, 1988. Rationale, mechanisms, and means.

Authors:  R J Havel
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

5.  Assembly of lipoprotein particles containing apolipoprotein-B: structural model for the nascent lipoprotein particle.

Authors:  Paul E Richardson; Medha Manchekar; Nassrin Dashti; Martin K Jones; Anne Beigneux; Stephen G Young; Stephen C Harvey; Jere P Segrest
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

Review 6.  Why are low-density lipoproteins atherogenic?

Authors:  S G Young; S Parthasarathy
Journal:  West J Med       Date:  1994-02

7.  Hypercholesterolemia in five Israeli Christian-Arab kindreds is caused by the "Lebanese" allele at the low density lipoprotein receptor gene locus and by an additional independent major factor.

Authors:  A Oppenheim; Y Friedlander; E J Dann; N Berkman; S P Schwartz; E Leitersdorf
Journal:  Hum Genet       Date:  1991-11       Impact factor: 4.132

8.  Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a).

Authors:  M F Linton; R V Farese; G Chiesa; D S Grass; P Chin; R E Hammer; H H Hobbs; S G Young
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: ApoE in ApoB-containing lipoproteins (Lp B:E) and ApoB in ApoE-containing lipoproteins (Lp E:B).

Authors:  C Y Yang; Y H Xie; M Yang; J A Quion; A M Gotto
Journal:  J Protein Chem       Date:  1995-10

Review 10.  Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy.

Authors:  M D Feher; D J Betteridge
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.